Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma

Table 6 Survival analysis with progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (n = 56)

Clinicopathologic variables	Univariate	Multivariate
Clinicopathologic variables	p value	p value	HR (95% CI)
Age
> 60 vs. ≤ 60	0.158
Sex
Male vs. female	0.702
ECOG PS
≥ 2 vs. < 2	< 0.001	< 0.001	21.553 (4.682–99.208)
B symptoms
Present vs. absent	0.099
Serum LDH
Elevated vs. normal	0.189
IPI
3–5 vs. 0–2	0.002	0.238
Primary site
Extranodal vs. nodal	0.204
Extranodal site
≥ 2 vs. < 2	< 0.001	0.167
Bone marrow involvement
Present vs. absent	0.476
Bulky mass
≥ 10 cm vs. < 10 cm	0.279
Ann Arbor stage
III–IV vs. I–II	0.037	0.610
Hans classification
Non-GCB vs. GCB	0.503
BCL2 expression
Positive vs. negative	0.983
BCL6 expression
Positive vs. negative	0.600
CD10 expression
Positive vs. negative	0.600
MUM1 expression
Positive vs. negative	0.409
PD-L1 tumor cell expression
Positive vs. negative	0.209
PD-L1 immune cell expression
Positive vs. negative	0.042	0.089
PD0L1 gene alteration
Present vs. absent	0.285

PD-L1: programmed cell death-ligand 1; pSTAT3: phosphorylated signal transducer and activator of transcription 3; ECOG PS: the Eastern Cooperative Group Performance Status; GCB: germinal center B-cell like; R-CHOP: rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone

ISSN: 1479-5876